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Background: Cells within breast cancer stem cell populations have been confirmed to have 
a CD44+CD24− phenotype. Strong expression of CD44 plays a critical role in numerous 
types of human cancers. CD44 is involved in cell differentiation, adhesion, and metastasis of 
cancer cells.
Methods: In this study, we reduced CD44 expression in CD44+CD24− breast cancer stem cells 
and investigated their sensitivity to an antitumor drug. The CD44+CD24− breast cancer stem cells 
were isolated from breast tumors; CD44 expression was downregulated with siRNAs followed 
by treatment with different concentrations of the antitumor drug.
Results: The proliferation of CD44 downregulated CD44+CD24− breast cancer stem cells was 
decreased after drug treatment. We noticed treated cells were more sensitive to doxorubicin, 
even at low doses, compared with the control groups.
Conclusions: It would appear that expression of CD44 is integral among the CD44+CD24− cell 
population. Reducing the expression level of CD44, combined with doxorubicin treatment, yields 
promising results for eradicating breast cancer stem cells in vitro. This study opens a new direc-
tion in treating breast cancer through gene therapy in conjunction with chemotherapy.
Keywords: antitumor drugs, breast cancer stem cells, CD44, CD44+CD24− cells, 
doxorubicin
Background
Cancer stem cells have been considered to be persistent in malignant tissues. The 
existence of cancer stem cells has been recently confirmed in solid tumors of the 
brain, prostate, pancreas, liver, colon, head and neck, lung, and skin.1–6 Breast cancer 
stem cells were identified as a cell population with a CD44+CD24− phenotype. This 
finding proved that as few as 100 cells with this phenotype could efficiently generate 
new tumors, while 20,000 cells without such marker expression did not form tumors.7 
The presence of a breast cancer stem cell population explained the minimal efficiency 
and high recurrence of conventional breast cancer treatments; breast cancer stem cells 
are able to resist chemotherapy and radiotherapy treatment. To date, various strategies 
have been developed to target these stem cells, utilizing differentiation and antitumor 
drug resistance therapy. We postulate that using antitumor drug resistance therapy 
to support chemotherapy would be a potential approach for more efficient cancer 
treatment. Numerous reports have shown that drug resistance involved inhibiting the 
expression of the ABCG2 protein.8–13 ABCG2 is a drug transporter on the membrane 
surface of cells. Inhibition of the expression of this channel results in an increase in 
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In this study, we wanted to evaluate the role of other 
genes and proteins in limiting propagation of CD44+CD24− 
breast cancer stem cells. The adhesion molecule, CD44, 
is a cell surface transmembrane glycoprotein involved in 
lymphocyte activation, recirculation and homing, adhesion 
of extracellular matrix, angiogenesis, and cell proliferation, 
differentiation, and migration.14 These properties are associ-
ated with the pathologic activities of cancer cells. As reported 
by Al-Hajj et al,7 cells that were strongly positive for CD44 
and negative for CD24 (CD44+CD24−/low) had tumorigenic 
and metastatic abilities in breast tumor tissue. We postulated 
that CD44 was a critical protein for breast cancer stem cells 
to retain their survival, multipotency, and other important 
properties, especially drug resistance.
Methods
cell culture and isolation  
of cD44+cD24− cells
Isolation and in vitro expansion of stem cells were carried 
out with breast tumor specimens obtained from consenting 
patients. Tumor biopsies were obtained at hospitals, then 
transferred to our laboratory. The biopsy samples were 
washed 3–4 times with phosphate-buffered saline (PBS), 
supplemented with 1X antibiotics and an antimycotic (Sigma-
Aldrich, St Louis, MO), and homogenized into small (approx-
imately 1–2 mm3) fragments. Homogenized samples were 
resuspended in M171 medium (Invitrogen, Carlsbad, CA) 
containing mammary epithelial growth supplement (MEGS; 
Invitrogen) and seeded into 35-mm culture dishes (Nunc, 
Roskilde, Denmark). Dishes were incubated at 37°C/5% 
CO2 and medium was refreshed every third day.
When confluency reached 70%, candidates for breast can-
cer stem cells were plated at a concentration of 1000 cells/mL 
in serum-free DMEM-F12, supplemented with 10 ng/mL 
basic fibroblast growth factor (bFGF), 20 ng/mL epidermal 
growth factor (EGF), 5 ng/mL insulin, and 0.4% bovine 
serum albumin (BSA). Cells grown under these conditions 
were nonadherent and formed spherical clusters of cells 
designated ‘spheres’ or ‘mammospheres,’ and were enzy-
matically dissociated every 3 days by incubation in a 0.25% 
trypsin-EDTA solution (Sigma-Aldrich) for 2 minutes at 
37°C to achieve a single cell suspension.
To purify the CD44+CD24− cell population, 1 mL cell 
suspensions in PBS (107 cells) were double stained with 20 
µL anti CD44-FITC and 20 µL anti CD24−PE. Samples were 
incubated in the dark and at room temperature for 45 minutes. 
CellQuest Pro software (BD Bioscience, Franklin Lakes, 
NJ) application was used to identify the CD44+CD24−/low 
cell population (Figure 1). This population was sorted into a 
50 mL tube coated with 1 mg/mL BSA. CD44+CD24− cells 
were harvested by centrifugation (3000 rpm, 5 minutes) and 
the population recovered by adherent culture in DMEM/
F12 supplemented with 10% fetal bovine serum (FBS) and 
1X antibiotic-mycotic (Sigma-Aldrich). The purity was con-
firmed by flow cytometry and samples with higher than 90% 
CD44+CD24− cells were used for further experiments.
Transient transfection of sirnA
The CD44 small interfering RNA (siRNA) sequences were 
5′-AGC TCT GAG CAT CGG ATT T-3′, 5′-TGG CTG ATC 
ATC TTG GCA T-3′, and 5′-CAC CTC CCA GTA TGA CAC 
A-3′. The siRNAs were transiently transfected with an siRNA 
Transfection kit (Santa Cruz Biotechnology, Inc, Santa Cruz, 
CA) following the manufacturer’s instructions. Briefly, 1 µg 
of the siRNA was mixed with 1 mL transfection medium and 
transfection reagent supplied with the kit, and incubated with 
2 × 105 adherent cells for 5–7 hours at 37°C/5% CO2. The 
medium was replaced with DMEM/F12 supplemented with 
20% FBS and 1% antibiotic-antimycotic, and incubated at 
37°C/5% CO2 for 18–24 hours. Finally, cells were cultured 
in fresh DMEM/F12 containing 10% FBS and 1% antibiotic-
antimycotic. After 48 hours of incubation, cells were ready 
for expression analysis of CD44.
rT-Pcr
Approximately 107 cells in the control and experimental 
groups were collected for total RNA isolation using a GeneJet 
RNA purification kit (Fermentas International Inc, Thermo 
Fisher Scientific, Ottawa, ON) according to the manufac-
turer’s instructions. The concentration of RNA was measured 
using a Biophotometer (Eppendorf, Hamburg, Germany). 
One-step RT-PCR was carried out using an Access RT-
PCR system kit (Promega, Madison, WI). The RT-PCR 
was performed in a 50 µL volume with a 45°C incubation 
for 30 minutes initially, followed by a 5-minute incubation 
at 95°C, then 30 cycles of 94°C for 45 seconds, 59°C for 
30 seconds, 72°C for 45 seconds, and a final extension step 
at 72°C for 5 minutes after cycle 30. The primer sequences 
AB C
1 mm 100 µm 100 µm
Figure  1  cells  were  primarily  cultured  from  breast  tumors  (A),  and  formed 
mammospheres when cultured under nonadherent conditions (B). cD44+cD24− 
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used for amplification of a 250 bp CD44 fragment were 
5′-ACA GCA CAG ACA GAA TCC CTG-3′ (forward) 
and 5′-TCT TCT GCC CAC ACC TTC TCC-3′ (reverse). 
  Amplification of a 94 bp fragment of the GAPDH gene was 
carried out with primers 5′-ACA GTC AGC CGC ATC TTC 
TT-3′ (forward) and 5′-ACG ACC AAA TCC GTT GAC 
TC-3′ reverse. The PCR products were separated on a 2% 
(w/v) agarose gel stained with ethidium bromide and visual-
ized under UV light (GelDot it, UVP, Upland, CA).
immunocytochemistry
Cells were fixed with 4% paraformaldehyde and washed three 
times with PBS. Fixed cells were incubated with a mouse 
antihuman CD44 antibody followed by a fluorescein isothio-
cyanate (FITC)-conjugated goat antimouse antibody (Santa 
Cruz Biotechnology Inc). For all the immunocytochemistry 
assays, negative staining controls involved omitting the 
primary antibody. Nuclei were stained with Hoescht 33342 
(Sigma-Aldrich). Images were captured using a Carl Zeiss 
microscope and a monochromatic cooled camera (Carl Zeiss, 
Oberkochen, Germany).
Antitumor drug treatment assay
Breast cancer stem cells (CD44+CD24−) with and without 
CD44 downregulation were seeded at a density of 0.4 × 104 
cells per well in 24-well plates (Nunc) in DMEMF12/10% 
FBS. After a 24-hour culture period, cells were treated with 0, 
1, 3, and 6 µg/mL doxorubicin (Sigma-Aldrich) for 48 hours. 
These cells were used to analyze the cell cycle, proliferation, 
and apoptosis.
Apoptosis and cell cycle analysis
Apoptosis was investigated by flow cytometry using 
annexin V and propidium iodide (PI; BD Biosciences), 
while cell cycle analysis was carried according to follow-
ing protocols. Cells in groups were washed twice in PBS 
and fixed in cold 70% ethanol for at least 3 hours at 4°C. 
Subsequently, cells were washed in PBS twice and stained 
with 1 mL of PI (20 µg/mL). A 50 µL volume of RNase A 
(10 µg/mL) was added to samples and incubated for 3 hours 
at 4°C. Stained cells were analyzed by flow cytometry using 
CellQuest Pro software.
Proliferation assay
Cells (5 × 105 cells/well) were seeded into 96-well microplates 
in DMEM/F12 supplemented with 10% FBS and 1% 
antibiotic-mycotic and incubated for 1, 3, and 5 days at 
37°C/5% CO2. A 10 µL volume of MTT (5 mg/mL) was 
added to each well for and left for 4 hours, then 150 µL DMSO 
was added to each well. The absorbance was measured with 
a multimode reader (Beckman Coulter, Brea, CA) at 595 nm 
and 620 nm. Samples were analyzed in triplicate.
statistical analysis
All experiments were performed in triplicate. The signifi-
cance of differences between mean values was assessed by 
the t-test and ANOVA. A P-value ,0.05 was considered to 
be significant. Data were analyzed by Statgraphics software 
(v 7.0; Statgraphics Graphics System, Warrenton, VA).
Results
isolation of cD44+cD24− cells from 
breast cancer biopsies
We carried out primary culture of 21 tumors from 21 differ-
ent patients, 15 samples exhibiting tumors that had grown 
with many single cells surrounding the tumor tissue. Cells 
from 15 samples were left to freely propagate until the cul-
ture reached 80% confluence. In most of the samples, single 
cells appeared around day 5, with the earliest at day 3. In the 
next stage, cells proliferated rapidly and combined clones 
were achieved at day 15. Two types of cells were observed 
in primary culture: epithelial cells with a bean shape and 
large nucleus, and stromal cells containing a smaller nucleus 
that were long, like fibroblasts (Figure 1A). When 15 pri-
mary cell samples were analyzed for the markers CD44 and 
CD24, all had a small population of cells positive for CD44 
and negative or weakly positive for CD24. On average, this 
population comprised 3.59% ± 1.65% of the total of cells 
derived from primary culture, the lowest proportion being 
1.25% and the highest 7.12% (n = 15). The results also 
showed that approximately 50% of cells were positive for 
CD24. However, .90% of cells were negative for CD44. 
Flow cytometry analysis indicated that most cells that were 
positive for CD44 were negative or weakly positive for 
CD24. When culturing primary cells in the mammosphere 
medium, many mammospheres were appearing in culture 
after 14 days (Figure 1B). Mammospheres were disaggre-
gated by trypsin and seeded under adherent conditions with 
uniform morphology (Figure 1C).
expression of cD44 after downregulation 
cD44+cD24− cells
Following siRNA transfection, total RNA was extracted 
to evaluate the expression of CD44 in transfected cells. 
Electrophoresis indicated a significant change in RT-PCR 
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not occur for the internal control gene (Figure 2A). The 
band intensity of PCR products analyzed by GelAnalyzer 
software showed that the signal of CD44 band decreased by 
nearly half compared with before knockdown (Figure 2E). 
This showed that CD44 siRNA transfection efficiently 
silenced RNA copies of CD44, thus reducing CD44 mes-
senger RNA (mRNA) level in treated cells. To investi-
gate the decrease in expression of CD44, we performed 
protein quantification by flow cytometry, which showed 
that the number of CD44 positive cells was reduced from 
93.65% ± 2.34% to 6.18% ± 2.39% (n = 3) (Figure 2B–C). 
The immunocytochemistry results revealed a similar trend 
after siRNA transfection (Figure 3).
characteristics of cD44+cD24− cells 
following cD44 downregulation and 
treatment with doxorubicin
cD44 knockdown cD44+cD24− cells slowly 
proliferated after treatment with doxorubicin
Treatment with doxorubicin had a suppressive effect on 
proliferation of CD44+CD24− cells where CD44 expression 
had been downregulated, whereas no change was seen in the 
control group. Figures 2D and 4 show that when doxorubicin 
was absent, proliferation rate was similar in the two groups 
with or without downregulation of CD44 after 3–5 days in 
culture. The effects of doxorubicin on normal cells were not 
observable at concentrations of 0, 1, and 3 µg/mL. At 6 µg/mL, 
proliferation inhibition became apparent; however, at this con-
centration, cells still proliferated at a moderate speed, with the 
OD value increasing from 0.24 ± 0.06 at day 1 to 0.49 ± 0.03 at 
day 5. In contrast, for the CD44 knockdown cells, doxorubicin 
effects were noticeable at concentrations of 1, 3, and 6 µg/mL. 
At a concentration of 1 µg/mL, cells grew at the same rate as 
cells without doxorubicin treatment and as well as those with 
1 µg/mL growth inhibitor. At concentrations of 3 and 6 µg/mL, 
cells showed no sign of proliferation, with necrosis observed. 
This led to a significant reduction in cell numbers in comparison 
with day 1. These data show that CD44+CD24− cells had strong 
resistance to doxorubicin. The resistance to doxorubicin was 
decreased by downregulation of CD44. Consequently, after 
treatment at a concentration of 1 µg/mL, proliferation of CD44 
knockdown cells was inhibited and higher concentrations of 
doxorubicin caused cell death (Figure 2D).
cD44 knockdown cD44+cD24− cells showed 
increased levels of apoptosis and alterations in the 
cell cycle
As shown in Figure 5, downregulation of CD44 expression 
caused apoptosis when doxorubicin was added. When the 
concentration of doxorubicin was 1, 3, and 6 µg/mL, the 
proportion of dead cells increased gradually to 2.33%, 4.13%, 
and 8.17%, respectively (Figure 5A–D). The apoptotic effect 
was obvious in CD44 knockdown cells, peaking at 34.19% 
dead cells when treated with 1 µg/mL doxorubicin. The level 
of apoptosis rose steadily and peaked at 40.2% when doxoru-
bicin was used at a concentration of 6 µg/mL (Figure 5E–H). 
Additionally, cells underwent cell cycle alteration, with the 
majority of normal cells in the G1/G0 phase and 10%–20% 
of cells in the S and G2/M phase. Unlike normal cells, CD44 
knockdown cells remained in the S phase, leading to a reduc-
tion in the proportion of cells in G0/G1 and G2/M. When a 
high concentration of agents was used, more cells terminated 
in the S phase (Figure 5).
Discussion
Breast cancer stem cells have been identified to have the 
CD44+CD24− phenotype.7 This is a rare population in 
malignant breast tumors, with numerous reports indicat-
ing that they are the origin of breast tumors. Breast cancer 
stem cells with this profile were shown to be capable of 
tumorigenicity, metastasis, and drug resistance.15–17 Based 
on the knowledge that CD44 plays a critical role in tumori-
genesis from other cancer studies, this work was performed 
to evaluate and compare the effects of a tumor-killing agent 
on CD44+CD24− breast cancer stem cells with knocked 
down CD44.
We isolated breast cancer cells with a CD44+CD24− 
phenotype from malignant tumors and enriched mammo-
spheres prior to harvesting and purifying cells of interest. 
We were able to obtain a CD44+CD24− cell population 
with a purity .90.05%. The highest and lowest levels of 
purity were 94.54% and 85.12%, respectively (n = 15). Of 
the 21 samples, we selected the purest sample (94.54%) for 
further experiments.
To decrease expression of CD44, we used siRNA; fol-
lowing CD44 siRNA transfection, cells were subjected to 
RT-PCR quantification and drug effects were investigated. 
Transfection of CD44 siRNA into CD44+CD24− cells reduced 
expression of the CD44. The semi-quantitative RT-PCR 
analysis and electrophoresis showed that CD44 mRNAs 
remaining in the cells was much lower compared with the 
original cells, while expression of the GAPDH internal 
control was unaltered. At a translational level, we used 
flow cytometry and immunocytochemistry to assess CD44 
expression. Results from these two techniques confirmed a 
noticeable reduction in CD44 expression. These results are 
consistent with a previous report that also used CD44 siRNA 
to monitor CD44 expression.18OncoTargets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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Cells verified as CD44 knockdown cells were treated 
with doxorubicin and compared with normal cells to confirm 
the role of CD44 in the breast cancer stem cell population. 
Doxorubicin is commonly used to treat some leukemias 
and Hodgkin’s lymphoma, as well as cancers of the bladder, 
breast, stomach, lung, ovaries, thyroid, soft tissue sarcoma, 
multiple myeloma, and others. Moreover because doxorubicin 
is extruded out via ABCG2 pumps, it is easy to evaluate the 
role of CD44 downregulation in further experiments. Doxo-
rubicin is therefore used in much research, especially on 
antitumor drug resistance.
The knockdown cells were more sensitive to doxorubicin 
compared with the original cells. Even at high doxorubicin 
concentrations, the drug failed to kill normal CD44+CD24− 
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Figure 2 expression of cD44 was markedly decreased after transfection with cD44 sirnA. The cD44 knockdown cD44+cD24− cells exhibited decreased expression of 
CD44 at a transcriptional level as confirmed by RT-PCR (A) and band intensity on agarose gel analyzed with gelAnalyzer software (E). At the translational level, this was 
confirmed by flow cytometry (C) and compared with cells where knockdown did not occur (B). The cD44 knockdown cells proliferated slowly with a decrease in the total 
number of cells compared with normal cells (D).
Notes: n1, n3, and n6 are normal cells cultured in medium supplemented with 0, 1, 3, and 6 µg/mL doxorubicin, respectively. K0, K1, K3, and K6 are knockdown cells 
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Figure 4 normal (A–D) and cD44 knockdown (E–H) cells were treated with doxorubicin at four different concentrations: 0 (A, E), 1 (B, F), 3 (C, G), and 6 µg/mL (D, H). 
Pictures were captured at day 3.
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Figure 5 results of apoptosis and cell cycle analysis in normal cells and cD44 knockdown cells that were treated with doxorubicin at 0 (A, E), 1 (B, F), 3 (C, G), and 
6 (D, H) µg/mL.
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Figure 3 expression of cD44 was decreased after transfection with cD44 sirnA. The cD44+cD24− cells strongly expressed cD44 protein (A, B, C, D) and cD44 was 
weakly expressed after knockdown (E, F, G, H). A, E) cells before and after sirnA transfection. B, F) nuclei were stained with hoescht 33342. C, G) cells were stained 
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cells, whereas it caused apoptosis in the CD44 siRNA-
transfected cells. This implies that the reduction of CD44 
expression levels was associated with a decrease in drug 
resistance. Reduction of CD44 expression made breast cancer 
stem cells more sensitive to anticancer agents.
CD44 is a transmembrane protein19 synthesized in 
multiple isoforms by mRNA splicing. Although CD44 
lacks domains critical for signal transmission, it has been 
demonstrated that it is necessary for homing, and contains 
some characteristics of leukemia stem cells.20,21 There is 
some evidence that CD44 supports independent adhesion in 
vitro and tumor development as well as metastasis in solid 
tumors.22–24 The tumor-stimulating function of CD44 occurs 
through costimulation with signals by growth factor receptors 
such as EGF receptor-2 (Her2), EGF receptor 1 (Her1), and 
hepatocyte growth factor (Met).25 CD44 was considered as 
a useful marker to detect and enrich cancer stem cells.7,26–29 
CD44-positive cells are tumorigenic and highly metastatic.7 
Additionally, the CD44 marker has also been used to isolate 
prostate,30,31 pancreas,4 and colorectal32 cancer stem cells.
One feature of cancer stem cells (CSCs) in tumors is 
high expression of ABC transporters, especially ABCG2. 
The ABC transporters protect cells from the effects of drugs 
through drug excretion. Thus, CSCs, with their special bio-
logical properties, are able to resist drugs, even those used 
in chemotherapy.33 In clinical treatment, chemotherapy can 
abolish most of the cells in a solid tumor. However, a small 
population of CSCs are drug resistant, possibly due to the 
presence of many ABC transporters that help to pump anti-
tumor drugs out of the cells. Increased expression of ABC 
transporters in CSCs led to export of Hoechst 33342 and 
Rhodamine 123, which were detected by flow cytometry. 
Those cells that expelled Hoechst 33342 as detected by flow 
cytometry were called a side population. In comparison with 
cells sensitive to drugs, the CD44+CD24− cell population 
has a high level of ABCG2. Therefore, several studies using 
siRNA demonstrated that ABCG2 gene knockdown can 
ablate the capacity for drug resistance.
In this current study, reduction of CD44 expression 
alleviated the drug-resistant ability in breast cancer stem 
cells. This showed that there was a correlation between 
drug resistance and CD44 expression or signal pathways 
related to this protein. Reducing CD44 expression inhibited 
proliferation and caused apoptosis, which was also con-
firmed in CD44-positive liver cancer cells34,35 and prostate 
cancer cells.36
Based on the results of this study, we propose that CD44 
can be a target for treating cancers, especially breast cancer. 
Using CD44 siRNAs against breast cancer stem cells with 
the CD44+CD24− phenotype may be an efficient gene 
therapy strategy for breast cancer. However the applica-
tion of gene therapy to knock out CD44 still faces various 
challenges as there are many cells in the human body posi-
tive for CD44. Therefore intratumoral gene therapy with 
a polyethylenimine/siRNA CD44 plasmid DNA complex 
would be the best choice in this case. In this strategy, DNA 
plasmids containing the CD44 sequence that can transcript 
to CD44 siRNAs are mixed with polyethylenimine. Then 
this complex can be directly injected into breast tumors. 
Polyethylenimine is used as a reagent to facilitate plasmids 
into the tumor cells.
Conclusions
Strong expression of CD44 in a breast cancer stem cell 
population with a CD44+CD24− phenotype plays a pivotal 
role in proliferation and drug resistance of malignant cells. 
In this study, the molecular mechanisms and signal path-
ways responsible for proliferation and drug resistance were 
downregulated by knocking down CD44. Our data suggest 
that decreasing CD44 expression made cancer cells more 
sensitive to anticancer drugs. A combination of gene therapy 
to reduce CD44 expression and chemotherapy mitigated 
drug resistance and caused apoptosis in treated cells. This 
could be a new targeted strategy to eradicate breast cancer 
stem cells.
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